Navigation Links
Chimerix Signs Worldwide License Agreement With Merck For CMX157, A Novel Candidate For The Treatment Of HIV
Date:7/24/2012

vir against all major HIV subtypes resistant to current therapies, which may allow activity against tenofovir-resistant viruses (e.g., K65R), and against HBV.  CMX157's novel structure results in decreased circulating levels of tenofovir, lowering systemic exposure and thereby reducing the potential for renal side effects.  CMX157 has completed a Phase 1 clinical trial in healthy volunteers, demonstrating a favorable safety, tolerability and drug distribution profile. 

About Chimerix
Led by an experienced antiviral drug development team, Chimerix is developing novel oral antiviral therapeutics with the potential to improve quality of life for patients in multiple settings, including transplant, oncology, acute care and global health.  The company's proprietary lipid technology has given rise to two clinical stage compounds, CMX001 and CMX157, which have demonstrated the potential for enhanced activity, bioavailability and safety compared to currently approved drugs. 

Chimerix's lead compound, CMX001, is a broad spectrum lipid acyclic nucleoside phosphonate that inhibits double-stranded DNA (dsDNA) viruses including cytomegalovirus (CMV), adenovirus, BK virus, herpes simplex virus and variola (smallpox).  CMX001 has completed Phase 2 clinical development for the prophylaxis of CMV and is in Phase 2 development for the preemption and treatment of adenovirus infection in hematopoietic stem cell transplant (HSCT) recipients.  To date, more than 750 patients have been dosed with CMX001 in controlled clinical trials and open-label treatment protocols.  Antiviral activity from completed and ongoing studies, coupled with the lack of myelotoxicity and nephrotoxicity that are associated with currently available therapies, indicate that CMX001 has the potential to improve outcomes for stem cell and solid organ transplant recipients.  Chimerix has completed an End of Phase 2 meeting with the FDA for CMX001 and is
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Chimerix Announces BK Virus Data In Late-Breaking Poster Session At The 24th International Congress Of The Transplantation Society
2. Chimerixs Broad Spectrum Antiviral Therapeutic, CMX001, Demonstrates Potential To Mitigate BK Virus Associated End-Organ Disease In Clinical Study
3. AtheroNova Signs Agreement for Development of Clinical Trial Supplies
4. Southern Research Signs Agreement with Apath, LLC to Conduct Preclinical Studies with Virus-Based HCV Screenings
5. VWR International, LLC Signs Agreement to Acquire basan Germany GmbH
6. Haemonetics Signs Definitive Agreement To Acquire Hemerus Medical, LLC
7. Haemonetics Signs Definitive Agreement to Acquire Pall Corporations Blood Collection, Filtration and Processing Product Lines For $551 Million
8. H. D. Smith Signs Three Year Prime Vendor Agreement with PharmacyGPO Buying Group
9. Bacterin International Signs Its Third National GPO Contract with Novation
10. MusclePharm Signs Pro Baseball Rookie Phenom Bryce Harper As Sponsored Athlete
11. Masimo Signs Pronto-7™ Distribution Deal with Henry Schein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... nebulizer is a medical device used for the treatment ... converts liquid medication into mist or aerosol. Thus, the ... patient when inhaled through the mouth or a face ... devices powered by electric current and rechargeable batteries. Factors ... fibrosis and growing number of geriatric population worldwide support ...
(Date:10/30/2014)... 2014 CTI BioPharma Corp. (CTI) (NASDAQ and MTA: ... September 30, 2014. "During the quarter, ... beginning of 2014 by securing a partner to accelerate the ... market into countries where we do not have a commercial ... this partnership will maximize the value of PIXUVRI for CTI ...
(Date:10/30/2014)... 2014 Today Eli Lilly and Company (NYSE: ... technology transfer program to increase the global supply of ... effort included Lilly donating manufacturing technology and know-how for ... , India , ... – all MDR-TB ,hot spots., It also served ...
Breaking Medicine Technology:Nebulizers Market (Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 2Nebulizers Market (Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 3CTI BioPharma Reports Third Quarter 2014 Financial Results 2CTI BioPharma Reports Third Quarter 2014 Financial Results 3CTI BioPharma Reports Third Quarter 2014 Financial Results 4CTI BioPharma Reports Third Quarter 2014 Financial Results 5CTI BioPharma Reports Third Quarter 2014 Financial Results 6CTI BioPharma Reports Third Quarter 2014 Financial Results 7CTI BioPharma Reports Third Quarter 2014 Financial Results 8CTI BioPharma Reports Third Quarter 2014 Financial Results 9CTI BioPharma Reports Third Quarter 2014 Financial Results 10CTI BioPharma Reports Third Quarter 2014 Financial Results 11CTI BioPharma Reports Third Quarter 2014 Financial Results 12Lilly Shares Insights from Decade-Long Technology Transfer Experience 2Lilly Shares Insights from Decade-Long Technology Transfer Experience 3Lilly Shares Insights from Decade-Long Technology Transfer Experience 4
... - Introgen,Therapeutics, Inc. (NASDAQ:INGN) today announced the publication ... survival,pathway impacts the anticancer activity of INGN 241. ... tumor killing effects of,INGN 241 in cell culture ... Introgen and The University of Texas M. D. ...
... 2007 - Genmab A/S (CSE: GEN),announced today that ... (HuMax-CD20™) in patients with rheumatoid,arthritis (RA) have been ... Congress of Rheumatology (EULAR). The oral,presentation, which will ... II study with ofatumumab, along with data,from the ...
Cached Medicine Technology:Preclinical Studies Identify Novel Approach for Enhancing the,Anticancer Activity of Introgen's INGN 241 2Preclinical Studies Identify Novel Approach for Enhancing the,Anticancer Activity of Introgen's INGN 241 3
(Date:10/30/2014)... comes to heart disease, a new study finds women are ... symptoms that spell trouble. "The main danger is that ... or advanced stage of heart disease, there are simply fewer ... and research fellow at the Harvard School of Public Health, ... Foundation of Canada. In the study, researchers talked to ...
(Date:10/30/2014)... Amy Norton HealthDay Reporter ... a common plastics, chemical during pregnancy may have effects on ... Researchers found that baby boys born to moms with greater ... shorter anogenital distance -- the space between the genitals and ... considered a marker of exposure to androgens ("male" hormones) during ...
(Date:10/30/2014)... Many U.S. colleges have indoor tanning salons on ... risk for skin cancer, researchers report. Tanning ... so colleges should adopt tanning-free policies, to help ... health efforts are needed to raise university administration ... indoor tanning poses to young adults in order ...
(Date:10/30/2014)... opinions about the Affordable Care Act are sharply divided ... voters are strongly in favor of the Affordable Care ... Democrats want the next Congress to move ahead with ... current law, while 44 percent want to expand the ... want the law repealed, and 27 percent want it ...
(Date:10/30/2014)... respects the fact that a patient,s body is ... Over a third of cancer patients experience psychosocial ... conditions. And, increasingly, care providers are exploring phone- ... mental health challenges. A University of Colorado Cancer ... Psycho-Oncology asks an important question: after decades ...
Breaking Medicine News(10 mins):Health News:Women Often Ignore Signs of Heart Trouble 2Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 2Health News:Plastics' Chemical May Affect Baby Boys' Genital Development 3Health News:Many U.S. Colleges Have Indoor Tanning Salons On, Near Campus: Study 2Health News:Voters' Views on Obamacare Split Along Party Lines 2Health News:Decades of research: Effectiveness of phone counseling for cancer patients still unknown 2
... day to analysis and expert thought, they may be able ... of the precise type of brain tumour they face. Now ... technique that can give a preliminary analysis of the precise ... the brain and nervous system and they account for 20% ...
... Rosemont, Ill. - June 17, 2008- Current protein recommendations ... newer research indicates that many adults may benefit from ... presented in a supplement in the May issue of ... describing the conclusions of a Protein Summit ...
... on invasion and migration in colorectal cancer cell line. This ... performed by a team led by Professor Ji-Kun Li from ... article to be published on April 21, 2008 in the ... of the main causes of cancer-related death in the world. ...
... 17 XTENT, Inc.,(Nasdaq: XTNT ) today announced ... the current issue of EuroIntervention was recognized by the,journal,s ... submitted to the,journal this past winter. Lutz Buellesfeld, M.D., ... of the study,s investigators, received,an award in conjunction with ...
... Ala., June 17 Emageon Inc.,(Nasdaq: EMAG ... for hospitals, healthcare networks and imaging facilities announced,today ... present at the,Jefferies 2nd Annual Healthcare Conference on ... 24th at 8:30 AM ET. The presentation will ...
... 17 Nutrition 21, Inc.,(Nasdaq: NXXI ), ... consumers manage blood sugar levels, improve cardiovascular health,enhance ... Skin,Rejuvenation(TM) a new Iceland Health-branded product. Skin Rejuvenation ... capsule form,designed to reduce, at the cellular level, ...
Cached Medicine News:Health News:Wavelets crunch through doctors' day long struggle to diagnose brain tumors 2Health News:Is it time to revisit the current protein recommendations? 2Health News:Is it time to revisit the current protein recommendations? 3Health News:XTENT Announces CUSTOM I Data Receives Recognition from EuroIntervention 2Health News:XTENT Announces CUSTOM I Data Receives Recognition from EuroIntervention 3Health News:Nutrition 21 Introduces New Product: Iceland Health Skin Rejuvenation(TM) 2Health News:Nutrition 21 Introduces New Product: Iceland Health Skin Rejuvenation(TM) 3
Adhesive tape sheets for sealing multiwell plates and blocks;...
Microwell Plate Accessories...
DMSO-resistant microplate sealing film...
Amplification Tape 96 featuring 3M adhesive technology. Good optical quality. Minimal autofluorescence. Certified RNase and DNase free....
Medicine Products: